{
    "nctId": "NCT04576143",
    "briefTitle": "Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer",
    "officialTitle": "Efficacy and Safety of Dose-dense Epirubicin and Cyclophosphamide Plus Paclitaxel as Neoadjuvant Chemotherapy for HER2-negative Early Breast Cancer\uff1aa Multicenter Randomized Controlled Trial",
    "overallStatus": "RECRUITING",
    "conditions": "HER2-negative Breast Cancer, Neoadjuvant Chemotherapy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 260,
    "primaryOutcomeMeasure": "pathological complete response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female aged 18-70 years old;\n2. Histological confirmed with unilateral invasive carcinoma (all pathological types are applicable), clinical stage IIA-IIIA;\n3. Definite reports on ER/PR/HER2 receptor showing all HER2 negative (HER2 is 0\\~1+ or 2+ but determined negative via fluorescence in situ hybridization (FISH) or chemiluminescent in situ hybridization (CISH) detected (no amplification) is defined as HER2 negative);\n4. According to RECIST 1.1, there is at least one measurable objective focus, tumor size \\> 2cm;\n5. Eastern Cooperative Oncology Group (ECOG) performance score is 0 or 1;\n6. Cardiac function: left ventricular ejection fraction (LVEF)\u226555%;\n7. Normal bone marrow function: White blood cell count \\> 4 \u00d7 10\\^9/l, neutrophil count \\> 1.5 \u00d7 10\\^9/l, platelet count \\> 100 \u00d7 10\\^9/l and hemoglobin 9g/dl;\n8. Normal liver and renal function: aspartate aminotransferase (AST) and ALT \u22642.5 folds of the upper limit of normal values, total bilirubin \u22641.5 folds of the upper limit of normal values; Serum creatinine \u22641.5 folds of the upper limit of normal value.\n9. Informed consent form signed.\n\nExclusion Criteria:\n\n1. HER2 is positive;\n2. Metastasis at any location;\n3. Previous neoadjuvant therapy, including chemotherapy, radiotherapy and hormone therapy;\n4. Severe systemic disease and/or uncontrollable infection, unable to be enrolled in this study;\n5. Known allergic or intolerable to chemotherapeutic agents;\n6. Previously suffering from malignant tumors within 5 years (except for basal cell carcinoma and cervical carcinoma in situ), including contralateral breast cancer;\n7. Cardiovascular disease: LVEF \\<50% (echocardiography) of New York Heart Association (NYHA) \u2265 grade 2;\n8. Pregnant and breast-feeding women; Pregnancy test showed positive results before drug administration after enrolling in to the study; Women at childbearing age refuse to take contraception measures during the treatment and 8 weeks after completion of treatment;\n9. Already enrolled into other clinical trials;\n10. The researchers judged the patients who were not suitable for this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}